Roger J. M. Brüggemann

Roger J. M. Brüggemann publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Roger J. M. Brüggemann sits on this spectrum.

Roger J. M. Brüggemann D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Roger J. M. Brüggemann sits on this spectrum.

Best Publications

• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

  A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning

  1524
  Citations

• Tackling the emerging threat of antifungal resistance to human health

  Unknown

  1283
  Citations

• Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

  Philipp Koehler;Matteo Bassetti;Arunaloke Chakrabarti;Sharon C.A. Chen;Sharon C.A. Chen

  894
  Citations

• Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

  Roger J. M. Bruggemann;Jan-Willem C. Alffenaar;Nicole M. A. Blijlevens;Eliane M. Billaud

  512
  Citations

• Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.

  Paul E. Verweij;Bart J.A. Rijnders;Roger J.M. Brüggemann;Elie Azoulay

  395
  Citations

• International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

  Paul E. Verweij;Michelle Ananda-Rajah;David Andes;Maiken C. Arendrup

  346
  Citations

• European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

  J.A. Maertens;C. Girmenia;R.J.M. Bruggemann;R.F. Duarte

  334
  Citations

• Antifungal drugs: What brings the future?

  Ruth Van Daele;Isabel Spriet;Joost Wauters;Johan Maertens

  216
  Citations

• Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.

  Malgorzata Mikulska;Diana Averbuch;Frederic Tissot;Catherine Cordonnier

  190
  Citations

• Diagnosing COVID-19-associated pulmonary aspergillosis.

  Paul E. Verweij;Jean Pierre Gangneux;Matteo Bassetti;Roger J.M. Brüggemann

  186
  Citations

• Therapeutic drug monitoring of voriconazole.

  Roger J M Brüggemann;J Peter Donnelly;Rob E Aarnoutse;Adilia Warris

  175
  Citations

• Pharmacokinetics and Pharmacodynamics of Posaconazole

  Lu Chen;Elke H. J. Krekels;Paul. E. Verweij;Jochem B. Buil

  159
  Citations

• ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children

  Adilia Warris;Thomas Lehrnbecher;Emmanuel Roilides;Elio Castagnola

  152
  Citations

• Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

  Paul E. Verweij;Paul E. Verweij;Roger J.M. Brüggemann;Elie Azoulay;Matteo Bassetti

  150
  Citations

• Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4

  Andreas H. Groll;Robert Townsend;Amit Desai;Nkechi Azie

  142
  Citations

• Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene

  Eleftheria Mavridou;Roger J. M. Brüggemann;Willem J. G. Melchers;Johan W. Mouton

  140
  Citations

• The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections

  T. Tängdén;V. Ramos Martín;T. W. Felton;E. I. Nielsen

  133
  Citations

• Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1.

  Nico A F Janssen;Rémy Nyga;Lore Vanderbeke;Cato Jacobs

  133
  Citations

• Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

  Eleftheria Mavridou;Roger J. M. Bruggemann;Willem J. G. Melchers;Paul E. Verweij

  120
  Citations

• Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B

  Andreas H Groll;Bart J A Rijnders;Thomas J Walsh;Jill Adler-Moore

  111
  Citations